When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory approval for a new vaccine candidate, CNBC reported. In April 2020, Pfizer and ...

Scientists have found that Pfizer's COVID-19 vaccine may increase the risk of serious eye damage, potentially leading to loss of sight, according to a recent study. The new research conducted by ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

The Food and Drug Administration is considering revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave ...

Parents in the United States who want to vaccinate their young children against Covid-19 may face a growing set of challenges this fall. The US Food and Drug Administration might not renew ...

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers. Pfizer, in particular, could be ...

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...

Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm (95% CI 15.8, 93.5) Efficacy of 74.8% from 1-day post-dose 4 ...